Advertisement

Comparative and Veterinary Pharmacogenomics

  • Carrie M. Mosher
  • Michael H. CourtEmail author
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 199)

Abstract

Pharmacogenomics is the study of the impact of genetic variation on drug effects, with the ultimate goal of achieving “personalised medicine”. Since the completion of the Human Genome Project, great strides have been made towards the goal of personalised dosing of drugs in people, as exemplified by the development of gene-guided dosing of the anticoagulant drug, warfarin. Although the pharmacogenomics of domestic animals is still at an early stage of development, there is great potential for advances in the coming years as the direct result of complete genome sequences currently being derived for many of the species of significance to veterinary and comparative medicine. This sequence information is being used to discover sequence variants in candidate genes associated with altered drug response, as well as to develop whole genome high density single nucleotide polymorphism arrays for genotype–phenotype linkage analysis. This review summarises the current state of veterinary pharmacogenomics research, including drug response variability phenotypes with either known genetic aetiology or strong circumstantial evidence for genetic involvement. Polymorphisms and rarer gene variants affecting drug disposition (pharmacokinetics) and drug effect (pharmacodynamics) are discussed. In addition to providing the veterinary clinician with useful information for the practise of therapeutics, it is envisaged that the increasing knowledge base will also provide a resource for individuals involved in veterinary and comparative biomedical research.

Keywords

Cytochrome P450 Drug metabolism Malignant hyperthermia N-acetyltransferase P-glycoprotein Pharmacogenomics Thiopurine methyltransferase UDP-glucuronosyltransferase 

References

  1. Aleman M, Riehl J, Aldridge BM, Lecouteur RA, Stott JL, Pessah IN (2004) Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia. Muscle Nerve 30:356–365PubMedGoogle Scholar
  2. Aleman M, Brosnan RJ, Williams DC, LeCouteur RA, Imai A, Tharp BR, Steffey EP (2005) Malignant hyperthermia in a horse anesthetized with halothane. J Vet Intern Med 19:363–366PubMedGoogle Scholar
  3. Aleman M, Nieto JE, Magdesian KG (2009) Malignant hyperthermia associated with ryanodine receptor 1 (C7360G) mutation in Quarter Horses. J Vet Intern Med 23:329–334PubMedGoogle Scholar
  4. Bellah JR, Robertson SA, Buergelt CD, McGavin AD (1989) Suspected malignant hyperthermia after halothane anesthesia in a cat. Vet Surg 18:483–488PubMedGoogle Scholar
  5. Berman MC, Harrison GG, Bull AB, Kench JE (1970) Changes underlying halothane-induced malignant hyperpyrexia in Landrace pigs. Nature 225:653–655PubMedGoogle Scholar
  6. Blaisdell J, Goldstein JA, Bai SA (1998) Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26:278–283PubMedGoogle Scholar
  7. Boukouvala S, Price N, Sim E (2002) Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 12:385–394PubMedGoogle Scholar
  8. Brunson DB, Hogan KJ (2004) Malignant hyperthermia: a syndrome not a disease. Vet Clin North Am Small Anim Pract 34:1419–1433PubMedGoogle Scholar
  9. Carson PE, Flanagan CL, Ickes CE, Alving AS (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124:484–485PubMedGoogle Scholar
  10. Corser RB, Coughtrie MWH, Jackson MR, Burchell B (1987) The molecular-basis of the inherited deficiency of androsterone UDP-glucuronyltransferase in Wistar rats. FEBS Lett 213:448–452PubMedGoogle Scholar
  11. Cosgrove SB, Eisele PH, Martucci RW, Gronert GA (1992) Evaluation of greyhound susceptibility to malignant hyperthermia using halothane-succinylcholine anesthesia and caffeine-halothane muscle contractures. Lab Anim Sci 42:482–485PubMedGoogle Scholar
  12. Court MH (1999) Anesthesia of the sighthound. Clin Tech Small Anim Pract 14:38–43PubMedGoogle Scholar
  13. Court MH (2007) A pharmacogenomics primer. J Clin Pharmacol 47:1087–1103PubMedGoogle Scholar
  14. Court MH, Hay-Kraus BL, Hill DW, Kind AJ, Greenblatt DJ (1999) Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. Drug Metab Dispos 27:1293–1299PubMedGoogle Scholar
  15. Curtis MB, Eicker SE (1991) Pharmacodynamic properties of succinylcholine in greyhounds. Am J Vet Res 52:898–902PubMedGoogle Scholar
  16. de Jong RH, Heavner JE, Amory DW (1974) Malignant hyperpyrexia in the cat. Anesthesiology 41:608–609PubMedGoogle Scholar
  17. de Morais SM, Wells PG (1989) Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency. Hepatology 10:163–167PubMedGoogle Scholar
  18. DeLeon JH, Martell KJ, Vatsis KP, Weber WW (1995) Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). Drug Metab Dispos 23:1354–1361Google Scholar
  19. Dietrich CG, Ottenhoff R, de Waart DR, Elferink R (2001) Lack of UGT1 isoforms in Gunn rats changes metabolic ratio and facilitates excretion of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine. Toxicol Appl Pharmacol 170:137–143PubMedGoogle Scholar
  20. Fakis G, Boukouvala S, Kawamura A, Kennedy S (2007) Description of a novel polymorphic gene encoding for arylamine N-acetyltransferase in the rhesus macaque (Macaca mulatta), a model animal for endometriosis. Pharmacogenet Genomics 17:181–188PubMedGoogle Scholar
  21. Ferguson RJ, Doll MA, Rustan TD, Hein DW (1996) Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyl-transferase encoding genes of the Syrian hamster. Pharmacogenetics 6:55–66PubMedGoogle Scholar
  22. Foster AP, Shaw SE, Duley JA, Shobowale-Bakre EM, Harbour DA (2000) Demonstration of thiopurine methyltransferase activity in the erythrocytes of cats. J Vet Intern Med 14:552–554PubMedGoogle Scholar
  23. Frymoyer JW, Jacox RF (1963) Studies of genetically controlled sulfadiazine acetylation in rabbit livers: possible identification of the heterozygous trait. J Lab Clin Med 62:905–909PubMedGoogle Scholar
  24. Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, Weiler JE, O’Brien PJ, MacLennan DH (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253:448–451PubMedGoogle Scholar
  25. Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH (1991) A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11:751–755PubMedGoogle Scholar
  26. Graham MJ, Bell AR, Crewe HK, Moorcraft CL, Walker L, Whittaker EF, Lennard MS (2003) mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 33:225–237PubMedGoogle Scholar
  27. Haque SJ, Petersen DD, Nebert DW, Mackenzie PI (1991) Isolation, sequence, and developmental expression of rat UGT2B2 – the gene encoding a constitutive UDP-glucuronosyltransferase that metabolizes etiocholanolone and androsterone. DNA Cell Biol 10:515–524PubMedGoogle Scholar
  28. Haraguchi K, Kato Y, Koga N, Degawa M (2004) Metabolism of polychlorinated biphenyls by Gunn rats: identification and serum retention of catechol metabolites. Chem Res Toxicol 17:1684–1691PubMedGoogle Scholar
  29. Harrison PK, Tattersall JEH, Gosden E (2006) The presence of atropinesterase activity in animal plasma. Naunyn Schmiedebergs Arch Pharmacol 373:230–236PubMedGoogle Scholar
  30. Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, Court MH (2000) Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 30:575–588PubMedGoogle Scholar
  31. Hernandez JS, Vanloon JA, Otterness DM, Weinshilboum RM (1990) Mouse thiopurine methyltransferase pharmacogenetics: correlation of immunoreactive protein and enzymatic activity. J Pharmacol Exp Ther 252:568–573PubMedGoogle Scholar
  32. Hildebrand SV, Howitt GA (1983) Succinylcholine infusion associated with hyperthermia in ponies anesthetized with halothane. Am J Vet Res 44:2280–2284PubMedGoogle Scholar
  33. Homma H, Kawai H, Kubota M, Matsui M (1992) Large deletion of androsterone UDP-glucuronosyltransferase gene in the inherited deficient strain of Wistar rats. Biochim Biophys Acta 1138:34–40PubMedGoogle Scholar
  34. Hu ZH, Wells PG (1992) In vitro and in vivo biotransformation and covalent binding of benzo(a)pyrene in Gunn and RHA rats with a genetic deficiency in bilirubin uridine diphosphate-glucuronosyltransferase. J Pharmacol Exp Ther 263:334–342PubMedGoogle Scholar
  35. Hugnet C, Bentjen SA, Mealey KL (2004) Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J Vet Pharmacol Ther 27:227–229PubMedGoogle Scholar
  36. Hunter RP, Radlinsky M, Koch DE, Corse M, Pellerin MA, Halstead J (2005) Plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in greyhounds. Am J Vet Res 66:1441–1445PubMedGoogle Scholar
  37. Ito T, Takahashi M, Sudo K, Sugiyama Y (2007) Marked strain differences in the pharmacokinetics of an α4β1 integrin antagonist, 4-[1-[3-chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01–4582), in Sprague-Dawley rats are associated with albumin genetic polymorphism. J Pharmacol Exp Ther 320:124–132PubMedGoogle Scholar
  38. Ito T, Takahashi M, Sudo K, Sugiyama Y (2009) Interindividual pharmacokinetics variability of the alpha(4)beta(1) integrin antagonist, 4-[1-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S) -pyrrolidine-2-yl]methoxybenzoic acid (D01–4582), in beagles is associated with albumin genetic polymorphisms. J Pharm Sci 98:1545–1555PubMedGoogle Scholar
  39. Iyanagi T, Watanabe T, Uchiyama Y (1989) The 3-methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a -1 frameshift mutation. J Biol Chem 264:21302–21307PubMedGoogle Scholar
  40. Jun K, Lee SB, Shin HS (2000) Insertion of a retroviral solo long terminal repeat in mdr-3 locus disrupts mRNA splicing in mice. Mamm Genome 11:843–848PubMedGoogle Scholar
  41. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA (2009) Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 24:656–664PubMedGoogle Scholar
  42. Kawase A, Fujii A, Negoro M, Akai R, Ishikubo M, Komura H, Iwaki M (2008) Differences in Cytochrome P450 and Nuclear Receptor mRNA Levels in Liver and Small Intestines between SD and DA Rats. Drug Metab Pharmacokinet 23:196–206PubMedGoogle Scholar
  43. Kidd LB, Salavaggione OE, Szumlanski CL, Miller JL, Weinshilboum RM, Trepanier L (2004) Thiopurine methyltransferase activity in red blood cells of dogs. J Vet Intern Med 18:214–218PubMedGoogle Scholar
  44. Kim MS, Liu DQ, Strauss JR, Capodanno I, Yao Z, Fenyk-Melody JE, Franklin RB, Vincent SH (2003) Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR- rats. Xenobiotica 33:1027–1042PubMedGoogle Scholar
  45. Kirmayer AH, Klide AM, Purvance JE (1984) Malignant hyperthermia in a dog: case report and review of the syndrome. J Am Vet Med Assoc 185:978–982PubMedGoogle Scholar
  46. Kitamura Y, Koto H, Matsuura S, Kawabata T, Tsuchiya H, Kusuhara H, Tsujimoto H, Sugiyama Y (2008) Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. Drug Metab Dispos 36:807–810PubMedGoogle Scholar
  47. Klein L (1975) A hot horse. Vet Anesth 2:41–42Google Scholar
  48. Klein L, Ailes N, Fackelman GE, Kellon E, Rosenberg H (1989) Postanesthetic equine myopathy suggestive of malignant hyperthermia. A case report. Vet Surg 18:479–482PubMedGoogle Scholar
  49. KuKanich B, Borum SL (2008a) The disposition and behavioral effects of methadone in Greyhounds. Vet Anaesth Analg 35:242–248PubMedGoogle Scholar
  50. KuKanich B, Borum SL (2008b) Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. Am J Vet Res 69:664–669PubMedGoogle Scholar
  51. KuKanich B, Coetzee JF, Gehring R, Hubin M (2007) Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. J Vet Pharmacol Ther 30:314–319PubMedGoogle Scholar
  52. Lasseur R, Grandemange A, Longin-Sauvageon C, Berny P, Benoit E (2007) Comparison of the inhibition effect of different anticoagulants on vitamin K epoxide reductase activity from warfarin-susceptible and resistant rat. Pestic Biochem Physiol 88:203–208Google Scholar
  53. Leach LM, Ellis M, Sutton DS, McKeith FK, Wilson ER (1996) The growth performance, carcass characteristics, and meat quality of halothane carrier and negative pigs. J Anim Sci 74:934–943PubMedGoogle Scholar
  54. Leary SL, Anderson LC, Manning PJ, Bache RJ, Zweber BA (1983) Recurrent malignant hyperthermia in a Greyhound. J Am Vet Med Assoc 182:521–522PubMedGoogle Scholar
  55. Leslie EM, Ghibellini G, Nezasa KI, Brouwer KLR (2007) Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR-) Wistar rats. Carcinogenesis 28:2650–2656PubMedGoogle Scholar
  56. MacLennan DH, Phillips MS (1992) Malignant hyperthermia. Science 256:789–794PubMedGoogle Scholar
  57. Manley SV, Kelly AB, Hodgson D (1983) Malignant hyperthermia-like reactions in three anesthetized horses. J Am Vet Med Assoc 183:85–89PubMedGoogle Scholar
  58. Marsh S, Van Booven DJ (2009) The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 85:139–141PubMedGoogle Scholar
  59. Martell KJ, Vatsis KP, Weber WW (1991) Molecular genetic basis of rapid and slow acetylation in mice. Mol Pharmacol 40:218–227PubMedGoogle Scholar
  60. Matsui M, Watanabe HK (1982) Classification and genetic expression of wistar rats with high and low hepatic microsomal UDP-glucuronosyltransferase activity towards androsterone. Biochem J 202:171–174PubMedGoogle Scholar
  61. Mealey KL, Meurs KM (2008) Breed distribution of the ABCB1–1Δ (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 233:921–924PubMedGoogle Scholar
  62. Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727–733PubMedGoogle Scholar
  63. Mealey KL, Northrup NC, Bentjen SA (2003) Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 223(1453–1455):1434Google Scholar
  64. Mealey KL, Munyard KA, Bentjen SA (2005) Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 131:193–196PubMedGoogle Scholar
  65. Mealey KL, Greene S, Bagley R, Gay J, Tucker R, Gavin P, Schmidt K, Nelson F (2008) P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine P-glycoprotein knockout model. Drug Metab Dispos 36:1073–1079PubMedGoogle Scholar
  66. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF (1988) Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 263:9310–9315PubMedGoogle Scholar
  67. Miranda PS, Bosma PJ (2009) Towards liver-directed gene therapy for crigler-najjar syndrome. Curr Gene Ther 9:72–82PubMedGoogle Scholar
  68. Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T (2004a) Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 14:769–773PubMedGoogle Scholar
  69. Mise M, Yadera S, Matsuda M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T (2004b) Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos 32:240–245PubMedGoogle Scholar
  70. Mise M, Hashizume T, Komuro S (2008) Characterization of substrate specificity of dog CYP1A2 using CYP1A2-deficient and wild-type dog liver microsomes. Drug Metab Dispos 36:1903–1908PubMedGoogle Scholar
  71. Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, Mealey KL, Pedersen NC (2004) Breed distribution and history of canine mdr1–1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA 101:11725–11730PubMedGoogle Scholar
  72. Nelson TE (1991) Malignant hyperthermia in dogs. J Am Vet Med Assoc 198:989–994PubMedGoogle Scholar
  73. Nieto JE, Aleman M (2009) A rapid detection method for the ryanodine receptor 1 (C7360G) mutation in quarter horses. J Vet Intern Med March 6th Epub ahead of printGoogle Scholar
  74. O’Brien PJ, Cribb PH, White RJ, Olfert ED, Steiss JE (1983) Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony. Can Vet J 24:172–177PubMedGoogle Scholar
  75. O’Brien PJ, Pook HA, Klip A, Britt BA, Kalow BI, McLaughlin RN, Scott E, Elliott ME (1990) Canine stress syndrome/malignant hyperthermia susceptibility: calcium-homeostasis defect in muscle and lymphocytes. Res Vet Sci 48:124–128PubMedGoogle Scholar
  76. Olsén L, Ingvast-Larsson C, Broström H, Larsson P, Tjälve H (2007) Clinical signs and etiology of adverse reactions to procaine benzylpenicillin and sodium/potassium benzylpenicillin in horses. J Vet Pharmacol Ther 30:201–207PubMedGoogle Scholar
  77. Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, Kato I, Yokokura T (2008) Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Cancer Chemother Pharmacol 61:595–605PubMedGoogle Scholar
  78. Otterness DM, Weinshilboum RM (1987a) Mouse thiopurine methyltransferase pharmacogenetics: Biochemical studies and recombinant inbred strains. J Pharmacol Exp Ther 243:180–186PubMedGoogle Scholar
  79. Otterness DM, Weinshilboum RM (1987b) Mouse thiopurine methyltransferase pharmacogenetics: monogenic inheritance. J Pharmacol Exp Ther 240:817–824PubMedGoogle Scholar
  80. Paul AJ, Tranquilli WJ, Seward RL, Todd KS Jr, DiPietro JA (1987) Clinical observations in collies given ivermectin orally. Am J Vet Res 48:684–685PubMedGoogle Scholar
  81. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, Schoenhard GL (1999) Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27:1133–1142PubMedGoogle Scholar
  82. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126–1128PubMedGoogle Scholar
  83. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP (1997) A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25:1539–1542PubMedGoogle Scholar
  84. Pelz HJ, Rost S, Hunerberg M, Fregin A, Heiberg AC, Baert K, MacNicoll AD, Prescott CV, Walker AS, Oldenburg J, Muller CR (2005) The genetic basis of resistance to anticoagulants in rodents. Genetics 170:1839–1847PubMedGoogle Scholar
  85. Pippert TR, Umbenhauer DR (2001) The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J Biochem Mol Toxicol 15:83–89PubMedGoogle Scholar
  86. Pohjanvirta R, Viluksela M, Tuomisto JT, Unkila M, Karasinska J, Franc M-A, Holowenko M, Giannone JV, Harper PA, Tuomisto J, Okey AB (1999) Physicochemical differences in the AH receptors of the most TCDD-susceptible and the most TCDD-resistant rat strains. Toxicol Appl Pharmacol 155:82–95PubMedGoogle Scholar
  87. Poland A, Glover E (1990) Characterization and strain distribution pattern of the murine Ah receptor specified by the Ah d and Ah b-3 alleles. Mol Pharmacol 38:306–312PubMedGoogle Scholar
  88. Poland A, Palen D, Glover E (1994) Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol Pharmacol 46:915–921PubMedGoogle Scholar
  89. Pulliam JD, Seward RL, Henry RT, Steinberg SA (1985) Investigating ivermectin toxicity in collies. Vet Med 80:33–40Google Scholar
  90. Rempel WE, Lu M, el Kandelgy S, Kennedy CF, Irvin LR, Mickelson JR, Louis CF (1993) Relative accuracy of the halothane challenge test and a molecular genetic test in detecting the gene for porcine stress syndrome. J Anim Sci 71:1395–1399PubMedGoogle Scholar
  91. Richter RJ, Jarvik GP, Furlong CE (2009) Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 235:1–9PubMedGoogle Scholar
  92. Riedesel DH, Hildebrand SV (1985) Unusual response following use of succinylcholine in a horse anesthetized with halothane. J Am Vet Med Assoc 187:507–508PubMedGoogle Scholar
  93. Ritter MJ, Ellis M, Hollis GR, McKeith FK, Orellana DG, Van Genugten P, Curtis SE, Schlipf JM (2008) Frequency of the HAL-1843 mutation of the ryanodine receptor gene in dead and nonambulatory-noninjured pigs on arrival at the packing plant. J Anim Sci 86:511–514PubMedGoogle Scholar
  94. Roberts MC, Mickelson JR, Patterson EE, Nelson TE, Armstrong PJ, Brunson DB, Hogan K (2001) Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology 95:716–725PubMedGoogle Scholar
  95. Robinson EP, Sams RA, Muir WW (1986) Barbiturate anesthesia in greyhound and mixed-breed dogs: comparative cardiopulmonary effects, anesthetic effects, and recovery rates. Am J Vet Res 47:2105–2112PubMedGoogle Scholar
  96. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27:977–989PubMedGoogle Scholar
  97. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, Tweedie DJ (1998) Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357:27–36PubMedGoogle Scholar
  98. Roy-Chowdhury J, Huang TJ, Kesari K, Lederstein M, Arias IM, Roy-Chowdhury N (1991) Molecular basis for the lack of bilirubin-specific and 3-methylcholanthrene-inducible UDP-glucuronosyltransferase activities in Gunn-rats. The two isoforms are encoded by distinct mRNA species that share an identical single base deletion. J Biol Chem 266:18294–18298PubMedGoogle Scholar
  99. Sakai N, Saito K, Sakamoto KQ, Ishizuka M, Fujita S (2009) Genetic basis of inter- and intrastrain differences in diazepam p-hydroxylation in rats. Drug Metab Dispos 37:268–271PubMedGoogle Scholar
  100. Salavaggione OE, Kidd L, Prondzinski JL, Szumlanski CL, Pankratz VS, Wang L, Trepanier L, Weinshilboum RM (2002) Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics. Pharmacogenetics 12:713–724PubMedGoogle Scholar
  101. Salavaggione OE, Yang C, Kidd LB, Thomae BA, Pankratz VS, Trepanier LA, Weinshilboum RM (2004) Cat red blood cell thiopurine S-methyltransferase: Companion animal pharmacogenetics. J Pharmacol Exp Ther 308:617–626PubMedGoogle Scholar
  102. Sams RA, Muir WW (1988) Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res 49:245–249PubMedGoogle Scholar
  103. Sams RA, Muir WW, Detra RL, Robinson EP (1985) Comparative pharmacokinetics and anesthetic effects of methohexital, pentobarbital, thiamylal, and thiopental in Greyhound dogs and non-Greyhound, mixed-breed dogs. Am J Vet Res 46:1677–1683PubMedGoogle Scholar
  104. Sartor LL, Bentjen SA, Trepanier L, Mealey KL (2004) Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J Vet Intern Med 18:117–118PubMedGoogle Scholar
  105. Sasaki Y, Ohsako S, Deguchi T (1991) Molecular and genetic analyses of arylamine N-acetyltransferase polymorphism of rabbit liver. J Biol Chem 266:13243–13250PubMedGoogle Scholar
  106. Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van dr Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502PubMedGoogle Scholar
  107. Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, Edwards RJ (1999) Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357–366PubMedGoogle Scholar
  108. Short CE, Paddleford RR (1973) Letter: malignant hyperthermia in the dog. Anesthesiology 39:462–463PubMedGoogle Scholar
  109. Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH (2003) Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos 31:1161–1169PubMedGoogle Scholar
  110. Sim E, Walters K, Boukouvala S (2008) Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev 40:479–510PubMedGoogle Scholar
  111. Simanainen U, Tuomisto JT, Tuomisto J, Viluksela M (2003) Dose-response analysis of short-term effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in three differentially susceptible rat lines. Toxicol Appl Pharmacol 187:128–136PubMedGoogle Scholar
  112. Stampfli HF, Quon CY (1995) Polymorphic metabolism of flestolol and other ester-containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res Commun Mol Pathol Pharmacol 88:87–97PubMedGoogle Scholar
  113. Stewart SL, Hogan K, Rosenberg H, Fletcher JE (2001) Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 59:178–184PubMedGoogle Scholar
  114. Sugamori KS, Brenneman D, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, Grant DM (2007) Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouse. Drug Metab Dispos 35:1064–1070PubMedGoogle Scholar
  115. Tasaki T, Iwata H, Kazusaka A, Fujita S (1998) Regio- and stereoselectivity in propranolol metabolism by dog liver microsomes and the expressed dog CYP2D15. J Biochem 123:747–751PubMedGoogle Scholar
  116. Tenmizu D, Endo Y, Noguchi K, Kamimura H (2004) Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica 34:835–846PubMedGoogle Scholar
  117. Tenmizu D, Noguchi K, Kamimura H (2006a) Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2, 3-d] pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs. Drug Metab Dispos 34:1811–1816PubMedGoogle Scholar
  118. Tenmizu D, Noguchi K, Kamimura H, Ohtani H, Sawada Y (2006b) The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2, 3-d]pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor. Drug Metab Dispos 34:800–806PubMedGoogle Scholar
  119. Tobin T, Blake JW, Tai CY, Sturma L, Arnett S (1976) Pharmacology of procaine in horse: Procaine esterase properties of equine plasma and synovial-fluid. Am J Vet Res 37:1165–1170PubMedGoogle Scholar
  120. Tranquilli WJ, Paul AJ, Seward RL (1989) Ivermectin plasma concentrations in collies sensitive to ivermectin-induced toxicosis. Am J Vet Res 50:769–770PubMedGoogle Scholar
  121. Trepanier LA, Ray K, Winand NJ, Spielberg SP, Cribb AE (1997) Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 54:73–80PubMedGoogle Scholar
  122. Trepanier LA, Cribb AE, Spielberg SP, Ray K (1998) Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene. Pharmacogenetics 8:169–179PubMedGoogle Scholar
  123. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, Beare CM (1997) Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88–94PubMedGoogle Scholar
  124. Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, Yoshida I, Kimura A, Sakisaka S, Adachi Y, Kuwano M (1998) Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 7:203–207PubMedGoogle Scholar
  125. Waldron-Mease E, Klein LV, Rosenberg H, Leitch M (1981) Malignant hyperthermia in a halothane-anesthetized horse. J Am Vet Med Assoc 179:896–898PubMedGoogle Scholar
  126. Walraven JM, Barker DF, Doll MA, Hein DW (2007) Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and functional characterization of a novel rNat3*2 genetic variant. Toxicol Sci 99:413–421PubMedGoogle Scholar
  127. Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN (2001) Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 11:123–134PubMedGoogle Scholar
  128. Watters JW, McLeod HL (2002) Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. Pharmacogenomics 3:781–790PubMedGoogle Scholar
  129. Watters JW, Zhang W, Meucci MA, Hou W, Ma MK, McLeod HL (2004) Analysis of variation in mouse TPMT genotype, expression and activity. Pharmacogenetics 14:247–254PubMedGoogle Scholar
  130. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, He W, Chen YJ, Makhijani V, Roth GT, Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, Lupski JR, Chinault C, Song XZ, Liu Y, Yuan Y, Nazareth L, Qin X, Muzny DM, Margulies M, Weinstock GM, Gibbs RA, Rothberg JM (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872–876PubMedGoogle Scholar
  131. White SD, Rosychuk RA, Outerbridge CA, Fieseler KV, Spier S, Ihrke PJ, Chapman PL (2000) Thiopurine methyltransferase in red blood cells of dogs, cats, and horses. J Vet Intern Med 14:499–502PubMedGoogle Scholar
  132. Wright AWE, Dickinson RG (2004) Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat. J Pharmacol Exp Ther 310:584–588PubMedGoogle Scholar
  133. Xiong H, Turner KC, Ward ES, Jansen PL, Brouwer KL (2000) Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR- rats. J Pharmacol Exp Ther 295:512–518PubMedGoogle Scholar
  134. Xu L, Tripathy A, Pasek DA, Meissner G (1998) Potential for pharmacology of ryanodine receptor/calcium release channels. Ann N Y Acad Sci 853:130–148PubMedGoogle Scholar
  135. Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN, Lopez JR (2006) Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 105:1164–1175PubMedGoogle Scholar
  136. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745–1751PubMedGoogle Scholar
  137. Zhou H, Brockington M, Jungbluth H, Monk D, Stanier P, Sewry CA, Moore GE, Muntoni F (2006) Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. Am J Hum Genet 79:859–868PubMedGoogle Scholar
  138. Zoran DL, Riedesel DH, Dyer DC (1993) Pharmacokinetics of propofol in mixed-breed dogs and greyhounds. Am J Vet Res 54:755–760PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Department of Pharmacology and Experimental TherapeuticsTufts University School of MedicineBostonUSA

Personalised recommendations